Bottom Line

Diagnostic reproducibility in the range of intraductal proliferative lesions is poor Even amongst breast pathology experts Even when specific criteria are used Particularly in the ADH/limited LG-DCIS realm

Significance on the core of ADH vs DCIS has fewer management implications than UDH vs ADH.

Still rely heavily on morphology alone. Deepers, IHC can sometimes help.So if in doubt, send it out! Or share.